is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis, and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time-efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.

Its products, as combination therapy with immuno-oncology agents, create a new and superior standard of care that blocks key mechanisms of drug resistance, stimulates the immune system to fight cancer, and prevents cancer from spreading.

ENB Therapeutics was founded in 2015 and is headquartered in New York, New York.